Our research identified the 5-hydroxytryptamine receptor 1B (HTR1B) as a crucial target in migraine development, with network pharmacology analysis highlighting its involvement in neurotransmitter release, ion channel activity, and intracellular signaling. Here, HTR1B is linked to migraine disorder.